• 1
    Sackett D, Straus S, Richardson W, Rosenberg W, Haynes R, editors. Diagnosis and screening. In: Evidence-based medicine: how to practice and teach EBM. 2nd edition. Philadelphia: Churchill Livingstone; 2000. pp. 6793.
  • 2
    U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011; 154: 35664.
  • 3
    Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1): CD001155.
  • 4
    Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;(1): CD004523.
  • 5
    Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea B, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002; 23: 5248.
  • 6
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 143441.
  • 7
    Nelson H, Haney E, Dana T, Bougatsos C, Chou R. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2010; 153: 113.
  • 8
    Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, Kalkwarf HJ, Langman CB, Plotkin H, Rauch F, Zemel BS, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008; 43: 111521.
  • 9
    National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [Internet]. Washington, DC: National Osteoporosis Foundation; 2010 Jan [cited 2012 Feb 23]. Available from:
  • 10
    Lim LS, Hoeksema LJ, Sherin K; ACPM Prevention Practice Committee. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med. 2009; 36: 36675.
  • 11
    American College of Obstetricians and Gynecologists, Women's Health Care Physicians. ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obstet Gynecol. 2004 Jan; 103(1): 20316. [Reaffirmed 2008].
  • 12
    Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010; 17: 2554; quiz 55–6.
  • 13
    Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW, Johnston CC Jr, Kleerekoper M, Lindsay R, Luckey MM, McClung MR, Nankin HR, Petak SM, Recker RR; AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003; 9: 54464.
  • 14
    Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE; Study of Osteoporotic Fractures Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012; 366: 22533.
  • 15
    Lewiecki EM, Laster AJ, Miller P, Bilezikian JP. More density testing is needed, not less. J Bone Miner Res. 2012; 27: 73942.
  • 16
    Curtis JR, Carbone L, Cheng H, Hayes B, Laster A, Matthews R, Saag KG, Sepanski R, Tanner SB, Delzell E. Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res. 2008; 23: 10617.
  • 17
    U.S. Census Bureau. Population Estimates. National Characteristics: Vintage 2009 [Internet]. Washington, DC: U.S. Census Bureau, U.S. Department of Commerce [updated 2011 Dec 8; cited 2012 Feb 23]. Available from
  • 18
    Bell KJ, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud K, Bauer DC. Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009; 338: b2266.
  • 19
    Cauley JA, Lui LY, Stone KL, Hillier TA, Zmuda JM, Hochberg M, Beck TJ, Ensrud KE. Longitudinal study of changes in hip bone mineral density in Caucasian and African-American women. J Am Geriatr Soc. 2005; 53: 1839.
  • 20
    National Center for Health Statistics. National Health and Nutrition Examination Survey: Osteoporosis [Internet]. Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; 2002 Dec 16 [cited 2012 Feb 23]. Available from
  • 21
    Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007; 22: 46575.
  • 22
    Nguyen TV, Center JR, Eisman JA. Femoral neck bone loss predicts fracture risk independent of baseline BMD. J Bone Miner Res. 2005; 20: 1195201.
  • 23
    Sornay-Rendu E, Munoz F, DuBoeuf F, Delmas PD. Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study. J Bone Miner Res. 2005; 20: 192935.
  • 24
    Hillier TA, Stone KL, Bauer DC, Rizzo JH, Pedula KL, Cauley JA, Ensrud KE, Hochberg MC, Cummings SR. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch Intern Med. 2007; 167: 15560.
  • 25
    Frost SA, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Timing of repeat BMD measurements: development of an absolute risk-based prognostic model. J Bone Miner Res. 2009; 24: 18007.
  • 26
    Hennekens C, Buring J. Screening. In: Mayrent S, editor. Epidemiology in medicine. 1st ed. Philadelphia: Lippincott Williams & Wilkins; 1987. p. 32747.
  • 27
    Hulley S, Cummings S, Browner W, Grady D, Hearst N, Newman T. Designing studies of medical tests. In: Designing clinical research. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 17593.
  • 28
    U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Procedure Manual. AHRQ Publication No. 08-05118-EF. July 2008 [Internet]. Washington, DC: U.S. Preventive Services Task Force (USPSTF), Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services; 2008 July [cited 2012 Feb 23]. Available from
  • 29
    Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993; 341: 725.
  • 30
    Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JP, Pols HA. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004; 34: 195202.
  • 31
    Van der Klift M, De Laet CE, McCloskey EV, Hofman A, Pols HA. The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2002; 17: 10516.
  • 32
    Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ 3rd, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005; 20: 118594.
  • 33
    U.S. Preventive Services Task Force. Update on Methods: Estimating Certainty and Magnitude of Net Benefit [Internet]. Available from
  • 34
    Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd. The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int. 2012; 23: 81120.
  • 35
    Berry SD, Kiel DP, Donaldson MG, Cummings SR, Kanis JA, Johansson H, Samelson EJ. Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study. Osteoporos Int. 2010; 21: 5360.
  • 36
    Donaldson MG, Cawthon PM, Lui LY, Schousboe JT, Ensrud KE, Taylor BC, Cauley JA, Hillier TA, Dam TT, Curtis JR, Black DM, Bauer DC, Orwoll ES, Cummings SR; Osteoporotic Fractures in Men (MrOS) Study Group. Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res. 2010; 25: 150611.
  • 37
    World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. FRAX: WHO Fracture Risk Assessment Tool [Internet]. University of Sheffield, Sheffield, UK [cited 2012 Feb 23]. Available from
  • 38
    Ensrud KE, Schousboe JT. Clinical practice. Vertebral fractures. N Engl J Med. 2011; 364: 163442.